Document:

EX-10.42

 Exhibit 10.42 

PURCHASE AGREEMENT 

THIS PURCHASE AGREEMENT (“Agreement”) is made as of the 12th day of January, 2015 by and among Aldeyra Therapeutics, Inc., a
Delaware corporation (the “Company”), and the Investors set forth on the signature pages affixed hereto (each an “Investor” and collectively the “Investors”). 

Recitals 
 A. The Company
and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the provisions of Regulation D (“Regulation D”), as promulgated by the U.S. Securities and Exchange
Commission (the “SEC”) under the Securities Act of 1933, as amended; and 
 B. The Investors wish to purchase, severally but not
jointly, from the Company, and the Company wishes to sell and issue to the Investors, upon the terms and conditions stated in this Agreement, (i) an aggregate of 1,113,080 shares of the Company’s Common Stock, par value $0.001 per share
(together with any securities into which such shares may, following Closing, be reclassified, whether by merger, charter amendment or otherwise, the “Common Stock”), at purchase price of $7.00 per share, and (ii) warrants to purchase
an aggregate of 1,113,080 shares of Common Stock (subject to adjustment) at an exercise price of $9.50 per share (subject to adjustment) in the form attached hereto as Exhibit A (the “Warrants”); and 

C. Contemporaneous with the sale of the Common Stock and Warrants, the parties hereto will execute and deliver a Registration Rights
Agreement, in the form attached hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which the Company will agree to provide certain registration rights under the Securities Act of 1933, as amended, and the rules
and regulations promulgated thereunder, and applicable state securities laws. 
 In consideration of the mutual promises made herein and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1. Definitions. In addition to those terms defined above and elsewhere in this Agreement, for the purposes of this Agreement, the
following terms shall have the meanings set forth below: 
 “Affiliate” means, with respect to any Person, any other Person
which directly or indirectly through one or more intermediaries Controls, is controlled by, or is under common Control with, such Person. 

“Agent” means Laidlaw & Company (UK) Ltd. 

 “Agent Related Persons” means any of the Agent’s directors, executive
officers, general partners, managing members or other officers participating in the offering of the Securities. 
 “Business
Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business. 

“Common Stock Equivalents” means any securities of the Company or its Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock. 
 “Company’s Knowledge” means the actual knowledge of the executive officers (as defined in Rule 405
under the 1933 Act) of the Company, after reasonable due inquiry. 
 “Confidential Information” means trade secrets,
confidential information and know-how (including but not limited to ideas, formulae, compositions, processes, procedures and techniques, research and development information, computer program code, performance specifications, support documentation,
drawings, specifications, designs, business and marketing plans, and customer and supplier lists and related information). 

“Control” (including the terms “controlling”, “controlled by” or “under common control with”)
means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 

“Effective Date” means the date on which the initial Registration Statement is declared effective by the SEC. 

“Insider” means each director, executive officer, other officer of the Company participating in the offering, any beneficial
owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, and any promoter connected with the Company in any capacity on the date hereof. 

“Intellectual Property” means all of the following: (i) patents, patent applications, patent disclosures and inventions
(whether or not patentable and whether or not reduced to practice); (ii) trademarks, service marks, trade dress, trade names, corporate names, logos, slogans and Internet domain names, together with all goodwill associated with each of the
foregoing; (iii) copyrights and copyrightable works; (iv) registrations, applications and renewals for any of the foregoing; and (v) proprietary computer software (including but not limited to data, data bases and documentation). 

“Material Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations,
financial condition or business of the Company and its Subsidiaries taken as a whole, or (ii) the ability of the Company to perform its obligations under the Transaction Documents. 

  
 -2- 

 “Material Contract” means any contract, instrument or other agreement to which
the Company or any of its Subsidiaries is a party or by which it is bound which is material to the business of the Company and its Subsidiaries, taken as a whole, including those that have been filed or were required to have been filed as an exhibit
to the SEC Filings pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K. 
 “Person” means an
individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not
specifically listed herein. 
 “Purchase Price” means Seven Million Seven Hundred Ninety One Thousand Five Hundred and
Sixty Dollars ($7,791,560). 
 “Registration Statement” has the meaning set forth in the Registration Rights Agreement.

 “Required Investors” means (i) prior to Closing the Investors who, together with their Affiliates, have agreed to
purchase a majority of the Securities to be sold hereunder and (ii) from and after the Closing the Investors beneficially owning (calculated in accordance with Rule 13d-3 under the 1934 Act without giving effect to any limitation on exercise of
the Warrants set forth therein) a majority of the aggregate outstanding Shares and Warrant Shares. 
 “SEC Filings” has the
meaning set forth in Section 4.6. 
 “Securities” means the Shares, the Warrants and the Warrant Shares. 

“Shares” means the shares of Common Stock being purchased by the Investors hereunder. 

“Subsidiary” of any Person means another Person, an amount of the voting securities, other voting ownership or voting
partnership interests of which is sufficient to elect at least a majority of its Board of Directors or other governing body (or, if there are no such voting interests, 50% or more of the equity interests of which) is owned directly or indirectly by
such first Person. 
 “Transaction Documents” means this Agreement, the Warrants and the Registration Rights Agreement.

 “Warrant Shares” means the shares of Common Stock issuable upon the exercise of the Warrants. 

  
 -3- 

 “1933 Act” means the Securities Act of 1933, as amended, or any successor
statute, and the rules and regulations promulgated thereunder. 
 “1934 Act” means the Securities Exchange Act of 1934, as
amended, or any successor statute, and the rules and regulations promulgated thereunder. 
 2. Purchase and Sale of the Shares and
Warrants. Subject to the terms and conditions of this Agreement, on the Closing Date, each of the Investors shall severally, and not jointly, purchase, and the Company shall sell and issue to the Investors, the Shares and Warrants in the
respective amounts set forth opposite the Investors’ names on the signature pages attached hereto in exchange for the Purchase Price as specified in Section 3 below. 

3. Closing. Upon confirmation that the other conditions to closing specified herein have been satisfied or duly waived by the
Investors, (i) the Company shall deliver to each Investor a certificate or certificates, registered in such name or names as such Investor may designate, representing the Shares and Warrants purchased by such Investor, and (ii) such
Investor shall cause a wire transfer in same day funds to be sent to the account of the Company as instructed in writing by the Company, in an amount representing such Investor’s pro rata portion of the Purchase Price as set forth on the
signature pages to this Agreement. The closing of the purchase and sale of the Shares and Warrants (the “Closing”) shall take place at the offices of Lowenstein Sandler LLP, 1251 Avenue of the Americas, 18th Floor, New York, New York
10020, or at such other location and on such other date as the Company and the Investors shall mutually agree. The date on which the Closing occurs is hereinafter referred to as the “Closing Date.” 

4. Representations and Warranties of the Company. The Company hereby represents and warrants to the Investors and the Agent that,
except as set forth in the schedules delivered herewith (collectively, the “Disclosure Schedules”): 
 4. 1 Organization, Good
Standing and Qualification. Each of the Company and its Subsidiaries is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and
authority to carry on its business as now conducted and to own or lease its properties. Each of the Company and its Subsidiaries is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the
conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary unless the failure to so qualify has not had and would not reasonably be expected to have a Material Adverse Effect. The Company has no
Subsidiaries. 
 4.2 Authorization. The Company has full power and authority and has taken or will take prior to the Closing, all
requisite action on the part of the Company, its officers, directors and stockholders necessary for (i) the authorization, execution and delivery of the Transaction Documents, (ii) the authorization of the performance of all obligations of
the Company hereunder or thereunder, and (iii) the authorization, issuance (or reservation for issuance) and delivery of the Securities. The Transaction Documents constitute the legal, valid and binding obligations of the Company, enforceable
against the Company in accordance with 

  
 -4- 

 
their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights
generally and to general equitable principles and except as rights to indemnity and contribution may be limited by state or federal securities laws or public policy. 

4.3 Capitalization. Schedule 4.3 sets forth as of the date hereof (a) the authorized capital stock of the Company;
(b) the number of shares of capital stock issued and outstanding; (c) the number of shares of capital stock issuable pursuant to the Company’s stock plans; and (d) the number of shares of capital stock issuable and reserved for
issuance pursuant to securities (other than the Shares and the Warrants) exercisable for, or convertible into or exchangeable for any shares of capital stock of the Company. All of the issued and outstanding shares of the Company’s capital
stock have been duly authorized and validly issued and are fully paid, nonassessable and free of pre-emptive rights and were issued in compliance with applicable state and federal securities law and any rights of third parties. Except as described
on Schedule 4.3, all of the issued and outstanding shares of capital stock of each of its Subsidiaries have been duly authorized and validly issued and are fully paid, nonassessable and free of pre-emptive rights, were issued in full
compliance with applicable state and federal securities law and any rights of third parties and are owned by the Company, beneficially and of record, subject to no lien, encumbrance or other adverse claim. Except as described on Schedule 4.3,
no Person is entitled to pre-emptive or similar statutory or contractual rights with respect to any securities of the Company. Except as described on Schedule 4.3 and except for the Registration Rights Agreement, there are no outstanding
warrants, options, convertible securities or other rights, agreements or arrangements of any character under which the Company or any of its Subsidiaries is or may be obligated to issue any equity securities of any kind and except as contemplated by
this Agreement, neither the Company nor any of its Subsidiaries is currently in negotiations for the issuance of any equity securities of any kind. Except as described on Schedule 4.3, there are no voting agreements, buy-sell agreements,
option or right of first purchase agreements or other agreements of any kind among the Company and any of the securityholders of the Company relating to the securities of the Company held by them. Except as described on Schedule 4.3 and
except for the Registration Rights Agreement, no Person has the right to require the Company to register any securities of the Company under the 1933 Act, whether on a demand basis or in connection with the registration of securities of the Company
for its own account or for the account of any other Person. 
 Except as described on Schedule 4.3, the issuance and sale of the
Securities hereunder will not obligate the Company to issue shares of Common Stock or other securities to any other Person (other than the Investors) and will not result in the adjustment of the exercise, conversion, exchange or reset price of any
outstanding security. 
 Except as described on Schedule 4.3, the Company does not have outstanding stockholder purchase rights or
“poison pill” or any similar arrangement in effect giving any Person the right to purchase any equity interest in the Company upon the occurrence of certain events. 

4.4 Valid Issuance. The Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be
validly issued, fully paid and 

  
 -5- 

 
nonassessable, and shall be free and clear of all encumbrances and restrictions (other than those created by the Investors), except for restrictions on transfer set forth in the Transaction
Documents or imposed by applicable securities laws. The Warrants have been duly and validly authorized. Upon the due exercise of the Warrants, including the payment of the exercise price or other exercise consideration thereunder, the Warrant Shares
will be validly issued, fully paid and non-assessable free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws and except for those
created by the Investors. The Company has reserved a sufficient number of shares of Common Stock for issuance upon the exercise of the Warrants. 

4.5 Consents. The execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of
the Securities require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other than filings that have been made pursuant to applicable state securities laws and post-sale filings pursuant
to applicable state and federal securities laws which the Company undertakes to file within the applicable time periods. Subject to the accuracy of the representations and warranties of each Investor set forth in Section 5 hereof, the Company
has taken all action necessary to exempt from the registration requirements of the Securities Act (i) the issuance and sale of the Securities, and (ii) the issuance of the Warrant Shares upon due exercise of the Warrants. The Company has
taken all action reasonably necessary to exempt the Investors from, the provisions of any stockholder rights plan or other “poison pill” arrangement, any anti-takeover, business combination or control share law or statute binding on the
Company or to which the Company or any of its assets and properties may be subject and any provision of the Company’s Certificate of Incorporation or Bylaws that is or would reasonably be expected to become applicable to the Investors as a
result of the transactions contemplated hereby, including without limitation, the issuance of the Securities and the ownership, disposition or voting of the Securities by the Investors or the exercise of any right granted to the Investors pursuant
to this Agreement or the other Transaction Documents. 
 4.6 Delivery of SEC Filings; Business. The Company has made available to the
Investors through the EDGAR system, true and complete copies of the Company’s Registration Statement on Form S-1 (File No. 333-193204) (the “S-1”), and all other reports filed by the Company pursuant to the 1934 Act since the
filing of the S-1 and through the date hereof (collectively with the S-1, each as amended prior to the date hereof, the “SEC Filings”). The SEC Filings are the only filings required of the Company pursuant to the 1934 Act for such period
and have been timely filed as required pursuant to the 1934 Act. The Company and its Subsidiaries are engaged in all material respects only in the business described in the SEC Filings and the SEC Filings contain a complete and accurate description
in all material respects of the business of the Company and its Subsidiaries, taken as a whole. 
 4.7 Use of Proceeds. The net
proceeds of the sale of the Shares and the Warrants hereunder shall be used by the Company for working capital and general corporate purposes. 

  
 -6- 

 4.8 No Material Adverse Change. Since December 31, 2013, except as identified and
described in the SEC Filings or as described on Schedule 4.8, there has not been: 
 (i) any change in the consolidated assets,
liabilities, financial condition or operating results of the Company from that reflected in the financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, except for changes in
the ordinary course of business which have not had and would not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; 

(ii) any declaration or payment of any dividend, or any authorization or payment of any distribution, on any of the capital stock of the
Company, or any redemption or repurchase of any securities of the Company; 
 (iii) any material damage, destruction or loss, whether or
not covered by insurance to any assets or properties of the Company or its Subsidiaries; 
 (iv) any waiver, not in the ordinary course of
business, by the Company or any of its Subsidiaries of a material right or of a material debt owed to it; 
 (v) any satisfaction or
discharge of any lien, claim or encumbrance or payment of any obligation by the Company or its Subsidiaries, except in the ordinary course of business and which is not material to the assets, properties, financial condition, operating results or
business of the Company and its Subsidiaries taken as a whole (as such business is presently conducted and as it is presently proposed to be conducted); 

(vi) any change or amendment to the Company’s Certificate of Incorporation or Bylaws, or material change to, or waiver of any material
right under, any material contract or arrangement by which the Company or any of its Subsidiaries is bound or to which any of their respective assets or properties is subject; 

(vii) any material labor difficulties or labor union organizing activities with respect to employees of the Company or any of its
Subsidiaries; 
 (viii) any material transaction entered into by the Company or its Subsidiaries other than in the ordinary course of
business; 
 (ix) the loss of the services of any key employee, or material change in the composition or duties of the senior management of
the Company or its Subsidiaries; or 
 (x) any other event or condition of any character that has had or would reasonably be expected to
have a Material Adverse Effect. 
 4.9 SEC Filings. 

(a) At the time of filing thereof, the SEC Filings complied as to form in all material respects with the requirements of the 1934 Act and did
not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not
misleading. 

  
 -7- 

 (b) Each registration statement and any amendment thereto filed by the Company since
January 1, 2014 pursuant to the 1933 Act and the rules and regulations thereunder, as of the date such statement or amendment became effective, complied as to form in all material respects with the 1933 Act and did not contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein not misleading; and each prospectus filed pursuant to Rule 424(b) under the 1933 Act, as of its
issue date and as of the closing of any sale of securities pursuant thereto did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made
therein, in the light of the circumstances under which they were made, not misleading. 
 4.10 No Conflict, Breach, Violation or
Default. The execution, delivery and performance of the Transaction Documents by the Company and the issuance and sale of the Securities will not (i) conflict with or result in a material breach or violation of (a) any of the terms and
provisions of, or constitute a default under the Company’s Articles of Incorporation or the Company’s Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investors through the
EDGAR system), or (b) any statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company, any Subsidiary or any of their respective assets or properties, or
(ii) material conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien, encumbrance or other adverse claim upon any of the properties or
assets of the Company or any Subsidiary or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any Material Contract. 

4.11 Tax Matters. The Company and each Subsidiary of the Company has timely prepared and filed all material tax returns required to
have been filed by the Company or such Subsidiary with all appropriate governmental agencies and timely paid all taxes shown thereon or otherwise owed by it. The charges, accruals and reserves on the books of the Company in respect of taxes for all
fiscal periods are adequate in all material respects, and there are no material unpaid assessments against the Company or any Subsidiary of the Company nor, to the Company’s Knowledge, any basis for the assessment of any additional taxes,
penalties or interest for any fiscal period or audits by any federal, state or local taxing authority except for any assessment which is not material to the Company and its Subsidiaries, taken as a whole. All taxes and other assessments and levies
that the Company or any Subsidiary of the Company is required to withhold or to collect for payment have been duly withheld and collected and paid to the proper governmental entity or third party when due. There are no tax liens or claims pending
or, to the Company’s Knowledge, threatened against the Company or any Subsidiary of the Company or any of their respective assets or property. Except as described on Schedule 4.11, there are no outstanding tax sharing agreements or
other such arrangements between the Company and any Subsidiary of the Company or other corporation or entity. 

  
 -8- 

 4.12 Title to Properties. Except as disclosed in the SEC Filings, the Company and each
Subsidiary of the Company has good and marketable title to all real properties and all other properties and assets owned by it, in each case free from liens, encumbrances and defects that would materially affect the value thereof or materially
interfere with the use made or currently planned to be made thereof by them; and except as disclosed in the SEC Filings, the Company and each Subsidiary of the Company holds any leased real or personal property under valid and enforceable leases
with no exceptions that would materially interfere with the use made or currently planned to be made thereof by them. 
 4.13
Certificates, Authorities and Permits. The Company and each Subsidiary of the Company possess adequate certificates, authorities or permits issued by appropriate governmental agencies or bodies necessary to conduct the business now operated
by it, the lack of which would not reasonably be expected to result in a Material Adverse Effect, individually or in the aggregate, and neither the Company nor any Subsidiary of the Company has received any notice of proceedings relating to the
revocation or modification of any such certificate, authority or permit that, if determined adversely to the Company or such Subsidiary of the Company, would reasonably be expected to have a Material Adverse Effect, individually or in the aggregate.

 4.14 Labor Matters. 

(a) Except as set forth on Schedule 4.14, the Company is not a party to or bound by any collective bargaining agreements or other
agreements with labor organizations. The Company has not violated in any material respect any laws, regulations, orders or contract terms, affecting the collective bargaining rights of employees, labor organizations or any laws, regulations or
orders affecting employment discrimination, equal opportunity employment, or employees’ health, safety, welfare, wages and hours, other than violations that would not reasonably be expected to be material, individually or in the aggregate. 

(b) (i) There are no labor disputes existing, or to the Company’s Knowledge, threatened, involving strikes, slow-downs, work stoppages,
job actions, disputes, lockouts or any other disruptions of or by the Company’s employees, (ii) there are no claims pertaining to unfair labor practices or petitions for election pending or, to the Company’s Knowledge, threatened
before the National Labor Relations Board or any other federal, state or local labor commission relating to the Company’s employees, (iii) no demand for recognition or certification heretofore made by any labor organization or group of
employees is pending with respect to the Company, (iv) to the Company’s Knowledge there exist no facts or circumstances that would reasonably be expected to give rise to the occurrence of any of the events described in clauses
(i) through (iii); and (v) to the Company’s Knowledge, the Company enjoys good labor and employee relations with its employees and labor organizations, 

(c) The Company is, and at all times since August 13, 2004 has been, in compliance in all material respects with all applicable laws
respecting employment (including laws relating to classification of employees and independent contractors) and employment practices, terms and conditions of employment, wages and hours, and immigration and naturalization. There are no claims
pending, or to the Company’s Knowledge threatened, against 

  
 -9- 

 
the Company before the Equal Employment Opportunity Commission or any other administrative body or in any court asserting any violation of Title VII of the Civil Rights Act of 1964, the Age
Discrimination Act of 1967, 42 U.S.C. §§ 1981 or 1983 or any other federal, state or local Law, statute or ordinance barring discrimination in employment. 

(d) Except as disclosed in the SEC Filings or as described on Schedule 4.14, the Company is not a party to, or bound by, any employment
or other contract or agreement that contains any severance, termination pay or change of control liability or obligation, including, without limitation, any “excess parachute payment,” as defined in Section 280G(b) of the Internal
Revenue Code. 
 (e) Except as specified in Schedule 4.14, each of the Company’s employees is a Person who is either a United
States citizen or a permanent resident entitled to work in the United States. The Company has no material liability for the improper classification by the Company of such employees as independent contractors or leased employees prior to the Closing.

 4.15 Intellectual Property. 

(a) All material Intellectual Property of the Company and its Subsidiaries is currently in compliance with all legal requirements (including
timely filings, proofs and payments of fees) and is valid and enforceable. No Intellectual Property of the Company or its Subsidiaries which is necessary for the conduct of Company’s and each of its Subsidiaries’ respective businesses as
currently conducted or as currently proposed to be conducted has been or is now involved in any cancellation, dispute or litigation, and, to the Company’s Knowledge, no such action is threatened. No patent of the Company or its Subsidiaries has
been or is now involved in any interference, reissue, re-examination or opposition proceeding. 
 (b) All of the licenses and sublicenses
and consent, royalty or other agreements concerning Intellectual Property which are necessary for the conduct of the Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be
conducted to which the Company or any Subsidiary of the Company is a party or by which any of their assets are bound (other than generally commercially available, non-custom, off-the-shelf software application programs having a retail acquisition price of less than $10,000 per license) (collectively, “License Agreements”) are valid and binding obligations of the Company
or its Subsidiaries that are parties thereto and, to the Company’s Knowledge, the other parties thereto, enforceable in accordance with their terms, except to the extent that enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights generally, and there exists no event or condition which will result in a material violation or breach of or constitute (with
or without due notice or lapse of time or both) a default by the Company or any of its Subsidiaries under any such License Agreement. 

(c) The Company and its Subsidiaries own or have the valid right to use all of the Intellectual Property that is necessary for the conduct of
the Company’s and each of 

  
 -10- 

 
its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted and for the ownership, maintenance and operation of the Company’s and its
Subsidiaries’ properties and assets, free and clear of all liens, encumbrances, adverse claims or obligations to license all such owned Intellectual Property and Confidential Information, other than licenses entered into in the ordinary course
of the Company’s and its Subsidiaries’ businesses. The Company and its Subsidiaries have a valid and enforceable right to use all third party Intellectual Property and Confidential Information used or held for use in the respective
businesses of the Company and its Subsidiaries. 
 (d) The conduct of the Company’s and its Subsidiaries’ businesses as currently
conducted does not infringe or otherwise impair or conflict with (collectively, “Infringe”) any Intellectual Property rights of any third party or any confidentiality obligation owed to a third party, and, to the Company’s Knowledge,
the Intellectual Property and Confidential Information of the Company and its Subsidiaries which are necessary for the conduct of Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed
to be conducted are not being Infringed by any third party. There is no litigation or order pending or outstanding or, to the Company’s Knowledge, threatened or imminent, that seeks to limit or challenge or that concerns the ownership, use,
validity or enforceability of any Intellectual Property or Confidential Information of the Company and its Subsidiaries and the Company’s and its Subsidiaries’ use of any Intellectual Property or Confidential Information owned by a third
party, and, to the Company’s Knowledge, there is no valid basis for the same. 
 (e) The consummation of the transactions contemplated
hereby and by the other Transaction Documents will not result in the alteration, loss, impairment of or restriction on the Company’s or any of its Subsidiaries’ ownership or right to use any of the Intellectual Property or Confidential
Information which is necessary for the conduct of Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted. 

(f) The Company and its Subsidiaries have taken reasonable steps to protect the Company’s and its Subsidiaries’ rights in their
Intellectual Property and Confidential Information. Each employee, consultant and contractor who has had access to Confidential Information of the Company which is necessary for the conduct of Company’s and each of its Subsidiaries’
respective businesses as currently conducted or as currently proposed to be conducted has executed an agreement to maintain the confidentiality of such Confidential Information and has executed appropriate agreements that are substantially
consistent with the Company’s standard forms thereof. Except under confidentiality obligations, to the Company’s Knowledge there has been no material disclosure of any of the Company’s or its Subsidiaries’ Confidential
Information to any third party. 
 4.16 Environmental Matters. Neither the Company nor any Subsidiary of the Company is in violation
of any statute, rule, regulation, decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the
environment or human exposure to hazardous or toxic substances (collectively, “Environmental Laws”), owns or 

  
 -11- 

 
operates any real property contaminated with any substance that is subject to any Environmental Laws, is liable for any off-site disposal or contamination pursuant to any Environmental Laws, or
is subject to any claim relating to any Environmental Laws, which violation, contamination, liability or claim has had or would reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; and there is no pending or,
to the Company’s Knowledge, threatened investigation by any governmental authority that might lead to such a claim. 
 4.17
Litigation. Except as described on Schedule 4.17, there are no pending actions, suits or proceedings against or affecting the Company, its Subsidiaries or any of its or their properties; and to the Company’s Knowledge, no such
actions, suits or proceedings are threatened. Neither the Company nor any Subsidiary of the Company, nor any director or officer thereof in his capacity as such, is or since January 1, 2009 has been the subject of any action involving a claim
of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the Company’s Knowledge, there is not pending or threatened, any investigation by the SEC involving the
Company or any current or former director or officer of the Company. The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary of the Company under the 1933
Act or the 1934 Act. 
 4.18 Financial Statements. The financial statements included in each SEC Filing comply in all material
respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent restatement) and present fairly, in all material respects,
the consolidated financial position of the Company as of the dates shown and its consolidated results of operations and cash flows for the periods shown, and such financial statements have been prepared in conformity with United States generally
accepted accounting principles applied on a consistent basis (“GAAP”) (except as may be disclosed therein or in the notes thereto, and, in the case of quarterly financial statements, as permitted by Form 10-Q under the 1934 Act). Except as
set forth in the financial statements of the Company included in the SEC Filings filed prior to the date hereof or as described on Schedule 4.18, neither the Company nor any of its Subsidiaries has incurred any liabilities, contingent or
otherwise, except those incurred in the ordinary course of business, consistent (as to amount and nature) with past practices since the date of such financial statements, none of which, individually or in the aggregate, have had or would reasonably
be expected to have a Material Adverse Effect. 
 4.19 Insurance Coverage. The Company and each Subsidiary of the Company maintains
in full force and effect insurance coverage that is customary for comparably situated companies for the business being conducted and properties owned or leased by the Company and each Subsidiary of the Company, and the Company reasonably believes
such insurance coverage to be adequate against all liabilities, claims and risks against which it is customary for comparably situated companies to insure. 

4.20 Compliance with Listing Requirements. The Common Stock is registered pursuant to Section 12(b) of the 1934 Act and is listed
on The NASDAQ Capital Markets (the “NASDAQ Capital Markets”), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the 1934 Act or

  
 -12- 

 
removal from listing of the Common Stock from the NASDAQ Capital Markets, nor has the Company received any notification that the SEC, the NASDAQ Capital Markets or the Financial Industry
Regulatory Authority, Inc. is contemplating terminating such registration or quotation. The Company is in compliance in all material respects with the listing and listing maintenance requirements of the NASDAQ Capital Markets applicable to it for
the continued trading of its Common Stock on the NASDAQ Capital Markets. 
 4.21 Brokers and Finders. Except for the Agent, no Person
will have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim against or upon the Company, any Subsidiary of the Company or an Investor for any commission, fee or other compensation pursuant
to any agreement, arrangement or understanding entered into by or on behalf of the Company. 
 4.22 No Directed Selling Efforts or
General Solicitation. Neither the Company nor any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or sale of any of the Securities.

 4.23 No Integrated Offering. Neither the Company nor any of its Affiliates, nor any Person acting on its or their behalf has,
directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any security, under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) for the exemption from registration
for the transactions contemplated hereby or would require registration of the Securities under the 1933 Act. 
 4.24 Rule 506
Compliance. Assuming the accuracy of the representations and warranties of the Investors set forth in Section 5 hereof, to the Company’s Knowledge, neither the Company nor any Insider, the Agent or any Agent Related Person is subject
to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2)(i) or (d)(3) of the 1933
Act. The Company is not disqualified from relying on Rule 506 of Regulation D under the 1933 Act (“Rule 506”) for any of the reasons stated in Rule 506(d) in connection with the issuance and sale of the Securities to the Investors pursuant
to this Agreement. The Company has exercised reasonable care, including without limitation, conducting a factual inquiry that is appropriate in light of the circumstances, into whether any such disqualification under Rule 506(d) exists. The Company
has furnished to each Investor, a reasonable time prior to the date hereof, a description in writing of any matters relating to the Company, the Insiders, the Agent and the Agent Related Persons that would have triggered disqualification under Rule
506(d) but which occurred before September 23, 2013, in each case, in compliance with the disclosure requirements of Rule 506(e). The Company has exercised reasonable care, including without limitation, conducting a factual inquiry that is
appropriate in light of the circumstances, into whether any such disqualification under Rule 506(d) would have existed and whether any disclosure is required to be made to Investor under Rule 506(e). Any outstanding securities of the Company (of any
kind or nature) that were issued in reliance on Rule 506 at any time on or after September 23, 2013 have been issued in compliance with Rule 506(d) and (e). 

  
 -13- 

 4.25 Private Placement. Assuming the accuracy of the representations and warranties of the
Investors set forth in Section 5, and in reliance thereon, the offer and sale of the Securities to the Investors as contemplated hereby is exempt from the registration requirements of the 1933 Act. 

4.26 Shell Company Status. The Company is not, and has never been, an issuer identified in Rule 144(i)(1). 

4.27 Questionable Payments. Neither the Company nor any of its Subsidiaries nor, to the Company’s Knowledge, any of
their respective current or former stockholders, directors, officers, employees, agents or other Persons acting on behalf of the Company or any Subsidiary of the Company, has on behalf of the Company or any Subsidiary of the Company or in connection
with their respective businesses: (a) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; (b) made any direct or indirect unlawful payments to any
governmental officials or employees from corporate funds; (c) established or maintained any unlawful or unrecorded fund of corporate monies or other assets; (d) made any false or fictitious entries on the books and records of the Company
or any Subsidiary of the Company; or (e) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment of any nature. 

4.28 Transactions with Affiliates. Except as disclosed in the SEC Filings or as disclosed on Schedule 4.28, none of the officers
or directors of the Company and, to the Company’s Knowledge, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary of the Company (other than as holders of stock options and/or warrants,
and for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring
payments to or from any officer, director or such employee or, to the Company’s Knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner. 

4.29 Internal Controls. Other than as otherwise set forth in the SEC Filings: (a) the Company is in material compliance with the
provisions of the Sarbanes-Oxley Act of 2002 currently applicable to the Company; (b) the Company has established disclosure controls and procedures (as defined in 1934 Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such
disclosure controls and procedures to ensure that material information relating to the Company, including its Subsidiaries, is made known to the Company’s certifying officers by others within those entities; (c) The Company has established
internal control over financial reporting (as defined in 1934 Act Rules 13a-15(f) and 15d-15(f)) to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with GAAP; and (d) the Company maintains and will continue to maintain a standard system of accounting established and administered in accordance with GAAP and the applicable requirements of the 1934 Act. The Company’s
certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by the most recently filed periodic report under the 1934 Act (such date, the “Evaluation
Date”). The Company presented in its most recently filed periodic report under the 

  
 -14- 

 
1934 Act the conclusions of the certifying officers about the effectiveness of such disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation
Date, there have been no significant changes in the Company’s disclosure controls and procedures or, to the Company’s Knowledge, in other factors that could significantly affect the Company’s disclosure controls and procedures. 

4.30 Disclosures. Neither the Company nor any Person acting on its behalf has provided the Investors or their agents or counsel with
any information that constitutes or might constitute material, non-public information, other than the terms of the transactions contemplated hereby. The written materials delivered to the Investors in connection with the transactions contemplated by
the Transaction Documents do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were made, not misleading.

 4.31 Investment Company. The Company is not required to be registered as, and is not an Affiliate of, and immediately following
the Closing will not be required to register as, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. 

4.32 FDA. The Company and each of its Subsidiaries have operated and currently are in compliance with all applicable rules and
regulations of the FDA or any other federal, state, local or foreign governmental body exercising comparable authority, except where the failure to so operate or be in compliance would not have a Material Adverse Effect. All preclinical and clinical
studies conducted by or, to the Company’s Knowledge, on behalf of the Company to support approval for commercialization of the Company’s products have been conducted by the Company, or to the Company’s Knowledge by third parties, in
compliance with all applicable federal, state or foreign laws, rules, orders and regulations, except for such failure or failures to be in compliance which would not reasonably be expected to have, singly or in the aggregate, a Material Adverse
Effect. The descriptions of the tests and preclinical and clinical studies, and results thereof, conducted by or, to the Company’s Knowledge, on behalf of the Company contained in the SEC Filings are accurate and complete in all material
respects; and the Company has not received any oral or written notice or correspondence from the FDA or any foreign, state or local governmental body exercising comparable authority requiring the termination, suspension, or clinical hold of any
tests or preclinical or clinical studies, or such written notice or correspondence from any Institutional Review Board or comparable authority requiring the termination or suspension of a clinical study, conducted by or on behalf of the Company,
which termination, suspension, or clinical hold would reasonably be expected to have a Material Adverse Effect. 
 5. Representations and
Warranties of the Investors. Each Investor hereby severally, and not jointly, represents and warrants to the Company that: 
 5.1
Organization and Existence. Such Investor is a validly existing corporation, limited partnership or limited liability company and has all requisite corporate, partnership or limited liability company power and authority to purchase the
Securities pursuant to this Agreement. 

  
 -15- 

 5.2 Authorization. The execution, delivery and performance by such Investor of the
Transaction Documents to which such Investor is a party have been duly authorized and each will constitute the valid and legally binding obligation of such Investor, enforceable against such Investor in accordance with their respective terms,
subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally. 

5.3 Purchase Entirely for Own Account. The Securities to be received by such Investor hereunder will be acquired for such
Investor’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and such Investor has no present agreement, understanding or intention of selling, granting any
participation in, or otherwise distributing the same in violation of the 1933 Act without prejudice, however, to such Investor’s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable
federal and state securities laws. Nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Securities for any period of time. Such Investor is not a broker-dealer registered with the SEC under the 1934 Act
or an entity engaged in a business that would require it to be so registered. 
 5.4 Investment Experience. Such Investor
acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment
contemplated hereby. 
 5.5 Disclosure of Information. Such Investor has had an opportunity to receive all information related to the
Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Securities. Such Investor acknowledges receipt of copies of the SEC Filings.
Neither such inquiries nor any other due diligence investigation conducted by such Investor shall modify, limit or otherwise affect such Investor’s right to rely on the Company’s representations and warranties contained in this Agreement
and the truth, accuracy and completeness thereof. 
 5.6 Restricted Securities. Such Investor understands that the Securities are
characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such
securities may be resold without registration under the 1933 Act only in certain limited circumstances. 
 5.7 Legends. It is
understood that, except as provided below, certificates evidencing the Securities may bear the following or any similar legend: 
 (a)
“The securities represented hereby have not been registered with the Securities and Exchange Commission or the securities commission of any state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and,
accordingly, may not be transferred unless (i) such securities have been registered for sale 

  
 -16- 

 
pursuant to the Securities Act of 1933, as amended, (ii) such securities may be sold pursuant to Rule 144, or (iii) the Company has received an opinion of counsel reasonably
satisfactory to it that such transfer may lawfully be made without registration under the Securities Act of 1933, as amended.” 
 (b)
If required by the authorities of any state in connection with the issuance of sale of the Securities, the legend required by such state authority. 

5.8 Investor Status. At the time such Investor was offered the Securities, it was, and at the date hereof it is, (i) an
“accredited investor” as defined in Rule 501(a) under the 1933 Act and (ii) an “institutional investor” as defined in Financial Industry Regulatory Authority Rule 5110(d)(4)(B). Such Investor is not a registered broker
dealer registered under Section 15(a) of the Exchange Act, or a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”) or an entity engaged in the business of being a broker dealer. Except as otherwise disclosed in
writing to the Company on or prior to the date of this Agreement, such Investor is not affiliated with any broker dealer registered under Section 15(a) of the 1934 Act, or a member of FINRA or an entity engaged in the business of being a broker
dealer. Such Investor maintains its principal executive office at the location specified on its signature page hereto. 
 5.9 No General
Solicitation. Such Investor did not learn of the investment in the Securities as a result of any general solicitation or general advertising. 

5.10 Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid
right, interest or claim against or upon the Company, any Subsidiary of the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Investor.

 5.11 Prohibited Transactions. Since the earlier of (a) such time as such Investor was first contacted by the Company or any
other Person acting on behalf of the Company regarding the transactions contemplated hereby or (b) thirty (30) days prior to the date hereof, neither such Investor nor any Affiliate of such Investor which (x) had knowledge of the
transactions contemplated hereby, (y) has or shares discretion relating to such Investor’s investments or trading or information concerning such Investor’s investments, including in respect of the Securities, or (z) is subject to
such Investor’s review or input concerning such Affiliate’s investments or trading (collectively, “Trading Affiliates”) has, directly or indirectly, effected or agreed to effect any short sale, whether or not against the box,
established any “put equivalent position” (as defined in Rule 16a-1(h) under the 1934 Act) with respect to the Common Stock, granted any other right (including, without limitation, any put or call option) with respect to the Common Stock
or with respect to any security that includes, relates to or derived any significant part of its value from the Common Stock or otherwise sought to hedge its position in the Securities (each, a “Prohibited Transaction”). Prior to the
earlier to occur of (i) the termination of this Agreement or (ii) the Effective Date, such Investor shall not, and shall cause its Trading Affiliates not to, engage, directly or indirectly, in a Prohibited Transaction. Such Investor
acknowledges that the representations, warranties and covenants contained in this 

  
 -17- 

 
Section 5.11 are being made for the benefit of the Investors as well as the Company and that each of the other Investors shall have an independent right to assert any claims against such
Investor arising out of any breach or violation of the provisions of this Section 5.11. 
 5.12 The Agent. Such Investor
understands that the Agent has acted solely as the agent of the Company in the placement of the Securities, and that the Agent makes no representation or warranty with regard to the merits of this transaction or as to the accuracy of any information
such Investor may have received in connection therewith. Such Investor acknowledges that it has not relied on any information or advice furnished by or on behalf of the Agent. 

6. Conditions to Closing. 

6.1 Conditions to the Investors’ Obligations. The obligation of each Investor to purchase the Shares and the Warrants at the
Closing is subject to the fulfillment to such Investor’s satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by such Investor (as to itself only): 

(a) The representations and warranties made by the Company in Section 4 hereof qualified as to materiality shall be true and correct at
all times prior to and on the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date, and, the
representations and warranties made by the Company in Section 4 hereof not qualified as to materiality shall be true and correct in all material respects at all times prior to and on the Closing Date, except to the extent any such
representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date. The Company shall have performed in all material respects
all obligations and covenants herein required to be performed by it on or prior to the Closing Date. 
 (b) The Company shall have obtained
any and all consents, permits, approvals, registrations and waivers necessary or appropriate for consummation of the purchase and sale of the Securities and the consummation of the other transactions contemplated by the Transaction Documents, all of
which shall be in full force and effect. 
 (c) No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice
or magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the
consummation of the transactions contemplated hereby or in the other Transaction Documents. 
 (d) The Company shall have delivered a
Certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a), (b), and (h) of this
Section 6.1. 

  
 -18- 

 (e) The Company shall have delivered a Certificate, executed on behalf of the Company by its
Secretary, dated as of the Closing Date, certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement and the other Transaction Documents and the issuance of the Securities,
certifying the current versions of the Certificate of Incorporation and Bylaws of the Company and certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company. 

(f) The Investors shall have received an opinion from Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, the
Company’s legal counsel, dated as of the Closing Date, in form and substance reasonably acceptable to the Investors and addressing such legal matters as the Investors may reasonably request. 

(g) The Company shall have executed and delivered the Registration Rights Agreement. 

(h) No stop order or suspension of trading shall have been imposed or threatened in writing by the NASDAQ Capital Markets, the SEC or any
other governmental or regulatory body with respect to public trading in the Common Stock. 
 6.2 Conditions to Obligations of the
Company. The Company’s obligation to sell and issue the Shares and the Warrants at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be
waived by the Company: 
 (a) The representations and warranties made by the Investors in Section 5 hereof, other than the
representations and warranties contained in Sections 5.3, 5.4, 5.5, 5.6, 5.7, 5.8 and 5.9 (the “Investment Representations”), shall be true and correct in all material respects when made, and shall be true and correct in all material
respects on the Closing Date with the same force and effect as if they had been made on and as of said date. The Investment Representations shall be true and correct in all respects when made, and shall be true and correct in all respects on the
Closing Date with the same force and effect as if they had been made on and as of said date. The Investors shall have performed in all material respects all obligations and covenants herein required to be performed by them on or prior to the Closing
Date. 
 (b) The Investors shall have delivered the Purchase Price to the Company. 

(c) The Investors shall have executed and delivered the Registration Rights Agreement. 

  
 -19- 

 6.3 Termination of Obligations to Effect Closing; Effects. 

(a) The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as follows:

 (i) Upon the mutual written consent of the Company and the Investors; 

(ii) By the Company if any of the conditions set forth in Section 6.2 shall have become incapable of fulfillment, and shall not have
been waived by the Company; 
 (iii) By an Investor (with respect to itself only) if any of the conditions set forth in Section 6.1
shall have become incapable of fulfillment, and shall not have been waived by the Investor; or 
 (iv) By either the Company or any
Investor (with respect to itself only) if the Closing has not occurred prior to 4:00 PM (New York time) on January 31, 2015; 
 provided, however,
that, except in the case of clause (i) above, the party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the
other Transaction Documents if such breach has resulted in the circumstances giving rise to such party’s seeking to terminate its obligation to effect the Closing. 

(b) In the event of termination by the Company or any Investor of its obligations to effect the Closing pursuant to this Section 6.3,
written notice thereof shall forthwith be given to the other Investors by the Company and the other Investors shall have the right to terminate their obligations to effect the Closing upon written notice to the Company and the other Investors.
Nothing in this Section 6.3 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel
specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. 
 7. Covenants and
Agreements of the Company. 
 7.1 Reservation of Common Stock. The Company shall at all times reserve and keep available out of
its authorized but unissued shares of Common Stock, solely for the purpose of providing for the exercise of the Warrants, such number of shares of Common Stock as shall from time to time equal the number of shares sufficient to permit the exercise
of the Warrants issued pursuant to this Agreement in accordance with their respective terms. 
 7.2 Reports. The Company will furnish
to the Investors and/or their assignees such information relating to the Company and its Subsidiaries as from time to time may reasonably be requested by the Investors and/or their assignees; provided, however, that the

  
 -20- 

 
Company shall not disclose material nonpublic information to the Investors, or to advisors to or representatives of the Investors, unless prior to disclosure of such information the Company
identifies such information as being material nonpublic information and provides the Investors, such advisors and representatives with the opportunity to accept or refuse to accept such material nonpublic information for review and any Investor
wishing to obtain such information enters into an appropriate confidentiality agreement with the Company with respect thereto. 
 7.3 No
Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment that would conflict or interfere in any material respect with the Company’s obligations to the Investors under the Transaction
Documents. 
 7.4 Insurance. The Company shall not materially reduce the insurance coverages described in Section 4.19. 

7.5 Compliance with Laws. The Company will comply in all material respects with all applicable laws, rules, regulations, orders and
decrees of all governmental authorities. 
 The provisions of Sections 7.2 through 7.5 shall terminate and be of no further force and effect on the date on
which the Company’s obligations under the Registration Rights Agreement to register or maintain the effectiveness of any registration covering the Registrable Securities (as such term is defined in the Registration Rights Agreement) shall
terminate. 
 7.6 Listing of Underlying Shares and Related Matters. Promptly following the date hereof, the Company shall use its
commercially reasonable efforts to take all necessary action to cause the Shares and the Warrant Shares to be included for listing on the NASDAQ Capital Market no later than the Closing Date. Further, if the Company applies to have its Common Stock
or other securities traded on any other stock exchange or market, it shall include in such application the Shares and the Warrant Shares and will take such other action as is necessary to cause such Common Stock to be so listed. The Company will use
commercially reasonable efforts to continue the public listing and trading of its Common Stock and, in accordance, therewith, will use commercially reasonable efforts to comply in all respects with the Company’s reporting, filing and other
obligations under the bylaws or rules of such market or exchange as the Common Stock is then listed or quoted, as applicable. 
 7.7
Removal of Legends. In connection with any sale or disposition of the Securities by an Investor pursuant to Rule 144 or pursuant to any other exemption under the 1933 Act such that the purchaser acquires freely tradable shares and upon
compliance by the Investor with the requirements of this Agreement, the Company shall or, in the case of Common Stock, shall cause the transfer agent for the Common Stock (the “Transfer Agent”) to issue replacement certificates
representing the Securities sold or disposed of without restrictive legends. Upon the earlier of (i) the effectiveness of the registration for resale pursuant to the Registration Rights Agreement or (ii) the Shares becoming freely tradable
by a non-affiliate pursuant to Rule 144, the Company shall (A) deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall reissue a certificate representing shares of Common Stock without legends upon receipt by such
Transfer Agent of the legended certificates for such 

  
 -21- 

 
shares, together with either (1) a customary representation by the Investor that Rule 144 applies to the shares of Common Stock represented thereby or (2) a statement by the Investor
that such Investor has sold the shares of Common Stock represented thereby in accordance with the plan of distribution contained in the Registration Statement, and (B) cause its counsel to deliver to the Transfer Agent one or more blanket
opinions to the effect that the removal of such legends in such circumstances may be effected under the 1933 Act. From and after the earlier of such dates (the “Legend Removal Date”), upon an Investor’s written request, the Company
shall promptly cause certificates evidencing the Investor’s Securities to be replaced with certificates which do not bear such restrictive legends, and Warrant Shares subsequently issued upon due exercise of the Warrants shall not bear such
restrictive legends provided the provisions of either clause (i) or clause (ii) above, as applicable, are satisfied with respect to such Warrant Shares. When the Company is required to cause an unlegended certificate to replace a
previously issued legended certificate, if: (1) the unlegended certificate is not delivered to an Investor within three (3) Business Days of submission by that Investor of a legended certificate and supporting documentation to the Transfer
Agent as provided above and (2) prior to the time such unlegended certificate is received by the Investor, the Investor, or any third party on behalf of such Investor or for the Investor’s account, purchases (in an open market transaction
or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Investor of shares represented by such certificate (a “Buy-In”), then the Company shall pay in cash to the Investor (for costs incurred either directly by
such Investor or on behalf of a third party) the amount by which the total purchase price paid for Common Stock as a result of the Buy-In (including brokerage commissions, if any) exceeds the proceeds received by such Investor as a result of the
sale to which such Buy-In relates. The Investor shall provide the Company written notice indicating the amounts payable to the Investor in respect of the Buy-In. Additionally, at the option of an Investor, the Company shall pay to such Investor, in
cash, as partial liquidated damages and not as a penalty, for each $1,000 of Shares or Warrant Shares (based on the Weighted Average Price (as defined in Exhibit A) of the Common Stock on the Legend removal date), $5 per trading day for each trading
day after the 2nd trading day following the Legend Removal Date until such certificate is delivered without a legend; provided, however, that such Investor has provided the Company with at least
one (1) trading day’s prior written notice of such failure to deliver certificates without legends. The foregoing shall be without prejudice to any other rights and recourses of any Investor in connection with the failure of the Company to
cause the prompt delivery to the Investor of unlegended certificates upon a written request therefor beginning on the Legend Removal Date. 

7.9 Registration Statements. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of
the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the 1933 Act) that will be integrated with the offer or sale of the Securities in a manner that would
require the registration under the 1933 Act of the sale of the Securities to the Investors, or that will be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any trading market such that it would
require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction. 

  
 -22- 

 7.10 Equal Treatment of Investors. No consideration shall be offered or paid to any Person
to amend or consent to a waiver or modification of any provision of any of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision
constitutes a separate right granted to each Investor by the Company and negotiated separately by each Investor, and is intended for the Company to treat the Investors as a class and shall not in any way be construed as the Investors acting in
concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise. 
 8. Survival and
Indemnification. 
 8.1 Survival. The representations, warranties, covenants and agreements contained in this Agreement shall
survive the Closing of the transactions contemplated by this Agreement. 
 8.2 Indemnification. The Company agrees to indemnify and
hold harmless each Investor and its Affiliates and their respective directors, officers, trustees, members, managers, employees and agents, and their respective successors and assigns, from and against any and all losses, claims, damages,
liabilities and expenses (including without limitation reasonable attorney fees and disbursements and other expenses incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the
costs of enforcement thereof) (collectively, “Losses”) to which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under the
Transaction Documents, and will reimburse any such Person for all such amounts as they are incurred by such Person. 
 8.3 Conduct of
Indemnification Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such
indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to
participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed to pay such fees or expenses, or (b) the indemnifying party shall have
failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such
person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying
party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party
of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in
connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except

  
 -23- 

 
with the consent of the indemnified party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or
plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation. 
 9. Miscellaneous. 

9.1 Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of the Company or
the Investors, as applicable, provided, however, that an Investor may assign its rights and delegate its duties hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of its Securities in a transaction complying with
applicable securities laws without the prior written consent of the Company or the other Investors. The provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties.
Without limiting the generality of the foregoing, in the event that the Company is a party to a merger, consolidation, share exchange or similar business combination transaction in which the Common Stock is converted into the equity securities of
another Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company” shall be deemed to refer to
such Person and the term “Shares” shall be deemed to refer to the securities received by the Investors in connection with such transaction. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the
parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

9.2 Counterparts; Faxes. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile, which shall be deemed an original. 

9.3 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 9.4 Notices. Unless otherwise provided, any notice required or permitted under this
Agreement shall be given in writing and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such delivery, (ii) if given by facsimile or electronic mail,
then such notice shall be deemed given upon receipt of confirmation of complete transmittal, (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or (B) three
days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one Business Day after delivery to such carrier. All
notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten days’ advance written notice to the other party: 

If to the Company: 
 Aldeyra
Therapeutics, Inc. 
 131 Hartwell Avenue, Suite 320 

Lexington, MA 02421 
 Attention:
Todd C. Brady 
 Email: tbrady@aldeyra.com 

  
 -24- 

 With a copy to: 

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP 

One Marina Park Drive, Suite 900 

Boston, MA 02210 
 Attention:
Keith J. Scherer 
 Fax: 617-648-9199 

If to the Investors: 
 to the addresses set
forth on the signature pages hereto. 
 9.5 Expenses. The parties hereto shall pay their own costs and expenses in connection
herewith, except that the Company shall pay the reasonable fees and expenses of Lowenstein Sandler LLP not to exceed $25,000, regardless of whether the transactions contemplated hereby are consummated; it being understood that Lowenstein Sandler LLP
has only rendered legal advice to the Agent and not to the Company or any Investor in connection with the transactions contemplated hereby, and that each of the Company and each Investor has relied for such matters on the advice of its own
respective counsel. Such expenses shall be paid upon demand. The Company shall reimburse the Investors upon demand for all reasonable out-of-pocket expenses incurred by the Investors, including without limitation reimbursement of attorneys’
fees and disbursements, in connection with any amendment, modification or waiver of this Agreement or the other Transaction Documents. In the event that legal proceedings are commenced by any party to this Agreement against another party to this
Agreement in connection with this Agreement or the other Transaction Documents, the party or parties to such proceeding which do not prevail in such proceedings shall severally, but not jointly, pay their pro rata share of the reasonable
attorneys’ fees and other reasonable out-of-pocket costs and expenses incurred by the prevailing party in such proceedings. 
 9.6
Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written
consent of the Company and the Investors. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Securities purchased under this Agreement at the time outstanding, each future holder of all such
Securities, and the Company. 

  
 -25- 

 9.7 Publicity. Except as set forth below, no public release or announcement concerning the
transactions contemplated hereby shall be issued by the Company or the Investors without the prior consent of the Company (in the case of a release or announcement by the Investors) or the Required Investors (in the case of a release or announcement
by the Company) (which consents shall not be unreasonably withheld), except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange or securities market, in which case the Company or
the Investors, as the case may be, shall allow the Investors or the Company, as applicable, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or announcement in advance of such issuance. On or
before 5:30 p.m., New York City time, on the date that this Agreement has been executed, the Company shall issue a press release reasonably acceptable to the Required Investors and, on or prior to 8:00 a.m., New York City time, on the next Business
Day, file a Current Report on Form 8-K describing the terms of the transactions contemplated by the Transaction Documents in the form required by the 1934 Act and attaching the material Transaction Documents (including, without limitation, this
Agreement (and all schedules and exhibits to this Agreement), the Form of Warrant and the Registration Rights Agreement, as exhibits to such filing (including all attachments), the “8-K Filing”). By 8:30 a.m. (New York City time) on
the trading day immediately following the Closing Date, the Company shall issue a press release disclosing the consummation of the transactions contemplated by this Agreement. No later than the fourth trading day following the Closing Date, the
Company will file a Current Report on Form 8-K attaching the press release described in the foregoing sentence. In addition, the Company will make such other filings and notices in the manner and time required by the SEC or the NASDAQ Capital
Markets and the Registration Rights Agreement. 
 9.8 Severability. Any provision of this Agreement that is prohibited or
unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be
enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by
applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect. 

9.9 Entire Agreement. This Agreement, including the Exhibits and the Disclosure Schedules, and the other Transaction Documents
constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter
hereof and thereof. 
 9.10 Further Assurances. The parties shall execute and deliver all such further instruments and documents and
take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained. 

9.11 Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance
with, the internal laws of the State 

  
 -26- 

 
of New York without regard to the choice of law principles thereof. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in
New York County and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of
process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably
consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought
in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION
WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER. 
 9.12 Independent
Nature of Investors’ Obligations and Rights. The obligations of each Investor under any Transaction Document are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the
performance of the obligations of any other Investor under any Transaction Document. The decision of each Investor to purchase Securities pursuant to the Transaction Documents has been made by such Investor independently of any other Investor.
Nothing contained herein or in any Transaction Document, and no action taken by any Investor pursuant thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a
presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Investor acknowledges that no other Investor has acted as agent for
such Investor in connection with making its investment hereunder and that no Investor will be acting as agent of such Investor in connection with monitoring its investment in the Securities or enforcing its rights under the Transaction Documents.
Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Investor
to be joined as an additional party in any proceeding for such purpose. The Company acknowledges that each of the Investors has been provided with the same Transaction Documents for the purpose of closing a transaction with multiple Investors and
not because it was required or requested to do so by any Investor. 
 [signature page follows] 

  
 -27- 

 IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized
officers to execute this Agreement as of the date first above written. 
  

							
	The Company:	 		 	ALDEYRA THERAPEUTICS, INC.
				
		 		 	By:	 	  

		 		 	Name:	 	
		 		 	Title:	 	

  
 -28- 

 
			
	  

	(Name of Investor)
		
	By:	 	  

	Name:	 	
	Title:	 	

 Aggregate Purchase Price: $         

Number of Shares: 
 Number of Warrants: 

Address for Notice: 

  
 -29-EX-10.1

 Exhibit 10.1 

EXECUTION COPY 

EXECUTIVE EMPLOYMENT AGREEMENT 

This Executive Employment Agreement (“Agreement”) is entered into this January 12, 2015, by and between Dana Holding
Corporation, a Delaware corporation, with its principal executive office at 3939 Technology Drive, Maumee, Ohio (the “Company”), and Roger Wood, an individual (“Executive”), effective as of the date first written above (the
“Effective Date”). 
 RECITALS 
  

	 	A.	Executive presently serves as President and Chief Executive Officer of the Company. 

  

	 	B.	Executive has announced his intention to retire from employment with the Company at the end of April, 2016. 

  

	 	C.	The Company desires the Executive to remain in his current positions until his retirement, and to assist the Company, as requested by the Board of Directors, in connection with the search for an appropriate successor
and in transitioning his duties and responsibilities to such successor. 

  

	 	D.	The Company and Executive desire to enter into this Agreement as to the terms of Executive’s employment by the Company to be effective as of the Effective Date. 

Therefore, in consideration of the promises and respective covenants and agreements of the parties herein contained, and intending to be
legally bound, the parties hereto agree as follows: 
  

	1.	Employment.    The Company and Executive hereby agree that as of the Effective Date Executive shall be employed by the Company on the terms set forth in this Agreement.

  

	2.	Term.    The employment of Executive by the Company under the terms of this Agreement shall commence on the Effective Date and shall continue in effect until April 30, 2016 (the
“Expiration Date”), unless earlier terminated as set forth in Section 6 of this Agreement (the period from the Effective Date through such termination shall hereinafter be referred to as the “Term”). 

 

	3.	Position and Duties.    Executive shall serve as President and Chief Executive Officer of the Company, reporting to the Board of Directors of the Company (“Board”), and shall
have such responsibilities and authority commensurate with such position as may from time to time be assigned to Executive by the Board. In addition, Executive shall assist the Board, to the extent requested, in connection with succession planning,
including, without limitation, the identification of a talented and appropriate successor to the office of President and Chief Executive Officer, and in the transition of Executive’s duties once the successor is identified. Executive shall
devote substantially all his working time and 

 
efforts to the business and affairs of the Company. However, Executive may devote reasonable time to supervision of his personal investments and professional, charitable, educational, religious
and other similar activities, and speaking engagements, and may also serve on the board of directors of any company or organization, provided such activities are not competitive with the Company and do not interfere with Executive’s discharge
of his duties to the Company. 
  

	4.	Directorship Agreement.    As of the Effective Date, Executive shall continue to serve as a member of the Board. The Board shall re-nominate Executive as a Director during such time as
Executive serves as President and Chief Executive Officer. Subject to Sections 6.3 and 6.6, after the first full calendar quarter to elapse following Executive’s ceasing to be President and Chief Executive Officer by virtue of the appointment
of his successor or his retirement in connection therewith, Executive shall immediately resign as a Director. 

  

	5.	Compensation and Related Matters. 

 During the Term, Executive shall be
entitled to the following compensation and benefits: 
  

	 	5.1	Salary.    The Company shall pay to Executive a salary of $1,025,000 per year (the “Base Salary”), which rate may be increased (but not decreased, except for across-the-board
decreases applicable with like proportionate effect to other senior executives of the Company) from time to time in accordance with normal business practices of the Company, at the discretion of the Board. The Base Salary shall be payable by the
Company in accordance with the normal payroll practices of the Company then in effect. Any increase or decrease in the Base Salary amount shall thereafter be Executive’s “Base Salary” for all purposes hereunder. 

 

	 	5.2	Bonus.    Executive shall be eligible for an annual bonus in 2015 with a target amount equal to 125% of Executive’s Base Salary (the “Target Bonus”) pursuant to the
Company’s 2012 Omnibus Incentive Plan, or any successor thereto (“Plan”). Executive’s actual bonus amount shall be based on the achievement of performance measures set by the Board of Directors. Executive shall also be eligible
to earn an additional 30% of the Executive’s Target Bonus under the personal performance program based on Executive’s support of the succession and transition process. Any bonus under this Section 5.2 shall be subject to the
provisions of Section 6.4 and 6.5 below. 

  

	 	5.3	Annual Long Term Incentive Program.    Executive shall be eligible for an annual award in 2015 pursuant to the Company’s long term incentive program under the Plan with a target
equal to 425% of base salary. Any such award shall be subject to the provisions of Sections 6.4 and 6.5 below. 

  

	 	5.4	Vacation.    In addition to legal holidays observed by the Company, Executive shall be entitled to twenty (20) days of paid vacation per year, which vacation days shall accrue and
be useable by Executive in accordance with the Company’s standard vacation policies. Upon termination of employment, the Company shall promptly pay Executive any accrued and unused vacation days. 

  
 2 

	 	5.5	Expenses.    Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by Executive in performing services hereunder, including all expenses of
travel and living expenses while away from home on business or at the request of and in the service of the Company, provided that such expenses are incurred and accounted for in accordance with the policies and procedures as reasonably established
by the Company. 

  

	 	5.6	Other Benefits.    Executive shall be entitled to participate in all of the Company’s benefit plans or arrangements, subject to the terms and conditions thereof, as in effect from
time to time with respect generally to senior executives; provided, Executive’s allowance for perquisites under the applicable perquisite program of the Company shall be in the amount of $50,000 for each fiscal year. 

 

	6.	Termination. 

  

	 	6.1	Termination for Any Reason.    Anything herein to the contrary notwithstanding, the Company may terminate Executive’s employment at any time for any reason with or without notice.
Executive may terminate his employment at any time for any reason after giving the Company not less than thirty (30) days prior notice of such termination. The Term of this Agreement shall terminate upon any termination of employment.

  

	 	6.2	Termination Upon Death or Disability.    Executive’s employment hereunder shall terminate upon his death. In the event that Executive’s employment terminates due to his death
or the Company terminates his employment due to Disability, he shall be entitled to (i) his accrued and unpaid Base Salary and accrued and unused vacation, payable not later than the first complete payroll payment date following such
termination, (ii) his unreimbursed business expenses incurred prior to such termination, payable in accordance with the policies and procedures applicable under Section 5.5 and (iii) his accrued and vested benefits under all employee
benefit plans in which Executive is a participant, payable in accordance with the terms of such plans (collectively, Executive’s “Accrued Obligations”). Executive shall also be entitled to any unpaid annual and long term cash bonus
earned for a completed previous performance period, payable when such bonuses are paid to other senior executives (“Prior Bonus”). Upon payment of the Accrued Obligations and the Prior Bonus, the Company shall have no further obligation to
Executive. For all purposes under this Agreement, “Disability” shall have the meaning set forth in the Company’s Executive Severance Plan (or successor to such plan). 

 

	 	6.3	Termination by the Company For Cause.    In the event that the Company terminates Executive’s employment for Cause, (i) Executive shall be entitled to his Accrued Obligations
and the Company shall have no further obligation to Executive and (ii) Executive shall immediately resign as a Director. 

  
 3 

	 	6.4	Appointment of a Successor During the Term. 

  

	 	6.4.1	In the event that Executive’s employment hereunder is terminated in connection with the Company’s appointment of a successor to the role of President and Chief Executive Officer, Executive shall be entitled to
(i) his Accrued Obligations and any Prior Bonus, (ii) continued payment of Executive’s Base Salary, payable in regular payroll installments over the period commencing on the date of Executive’s termination and ending on the
Expiration Date, (iii) if such termination occurs during 2015, a bonus for 2015 equal to the bonus Executive would have received for such year based on actual performance under the annual incentive program, including the personal objective
component, calculated as if Executive were employed for the entire year, and paid when annual bonuses are paid to other senior executives, and (iv) medical, dental, prescription drug, basic life insurance and employee assistance program
benefits through the Expiration Date, subject to Executive’s payment of any required employee contributions consistent with those contributions required of active employees of the Company (and which benefits shall be coterminous with
Executive’s entitlement to COBRA health benefits continuation). 

  

	 	6.4.2	Upon termination of Executive’s employment under this Section 6.4, (i) all of the Executive’s stock options shall vest and all such stock options shall remain exercisable until 10 years from their
respective dates of grant and (ii) for purposes of Executive’s restricted stock unit awards, Executive shall be treated as if he had terminated employment on the Expiration Date and as if he was eligible for Normal Retirement (as such term
is defined in Executive’s Restricted Stock Unit Agreement) on such date, and any restricted stock units that become nonforfeitable based on Normal Retirement under this Section 6.4.2 shall be settled at the time provided in the Restricted
Stock Unit Agreement, (iii) for purposes of Executive’s unvested performance cash awards and performance share awards (a) with respect to any performance year completed prior to the Expiration Date, Executive shall be entitled to
receive the full amount earned for each such year at the time that such amounts would otherwise have been paid to participants in the Company’s long-term incentive program under the Plan (provided, that such amounts shall not result in a
duplication of any long-term cash bonus amounts paid as part of the Prior Bonus), (b) with respect to any performance years that include the Expiration Date, Executive shall be entitled to receive the amount Executive would have received for
such year based on actual performance for the year of termination multiplied by the ratio of the number full months elapsed between the commencement of the performance period and the Expiration Date and the number of months in the performance period
and (c) any performance cash awards earned under this Section 6.4.2 shall be paid at the time that such awards would otherwise have been paid to participants in the Company’s long-term incentive program under the Plan and
(iv) Executive shall be deemed to have satisfied the requisite term of service and all other conditions for vesting and distribution under the terms of the Supplemental Executive Retirement Plan (the “SERP”). 

  
 4 

	 	6.4.3	Other than payment of the amounts and benefits provided under this Section 6.4, the Company shall have no further obligation to Executive. 

 

	 	6.4.4	The payments and benefits provided under clauses (ii), (iii) and (iv) of Section 6.4.1 and under Section 6.4.2 shall be subject to Executive entering into a complete release of all claims in the form
then applicable under the Company’s Executive Severance Plan (or any successor to such plan). All amounts payable under this Section 6.4 shall be in lieu of and not in addition to any amount that otherwise might be payable under the
Company’s Executive Severance Plan (or successor to such plan) upon such a termination. 

  

	 	6.5	Termination by the Company Without Cause; by Executive for Good Reason. 

  

	 	6.5.1	In the event that the Company terminates Executive’s employment hereunder without Cause (and not due to Disability) or Executive terminates his employment hereunder for Good Reason, Executive shall be entitled to
the payments and benefits provided for under Section 6.4.1 and 6.4.2 above. 

  

	 	6.5.2	Other than payment of the amounts and benefits provided under this Section 6.5, the Company shall have no further obligation to Executive. 

 

	 	6.5.3	For all purposes under this Agreement, “Cause” shall mean and include (i) a willful and material misappropriation of any monies or assets or properties of the Company; (ii) a willful and material
breach by Executive of the terms of this Agreement that is demonstrably injurious to the Company and that has not been cured within thirty (30) days after written notice to Executive of the breach, which notice shall specify the breach and the
nature of conduct necessary to cure such breach; or (iii) the conviction of, or plea of guilty or nolo contendre, by Executive to a felony or to any criminal offense involving Executive’s moral turpitude. 

 

	 	6.5.4	 For all purposes under this Agreement, “Good Reason” shall mean the occurrence of any of the following without the Executive’s consent:
(i) any material adverse change by the Company in Executive’s title, position, authority or reporting relationships with the Company; provided that any adverse change in Executive’s title, position, authority or reporting
relationships associated with the Company’s succession planning and the transition to a successor President and Chief Executive Officer shall not constitute Good Reason hereunder; (ii) the Company’s requirement that Executive relocate
to a location in excess of fifty (50) miles from the Company’s current office location or from any future office location 

  
 5 

	 	
acceptable to Executive; or (iii) any material breach by the Company of this Agreement which is not cured within thirty (30) days after written notice thereof by Executive to the
Company, which notice shall specify the breach and the nature of conduct necessary to cure such breach. 

  

	 	6.5.5	The payments and benefits provided pursuant to Sections 6.5.1 (other than the Accrued Obligations and Prior Bonus) shall be subject to Executive entering into a complete release of all claims in the form then applicable
under the Company’s Executive Severance Plan (or any successor to such plan). All amounts payable under this Section 6.5 shall be in lieu of and not in addition to any amount that otherwise might be payable under the Company’s
Executive Severance Plan (or successor to such plan) upon such a termination. 

  

	 	6.6	Termination By Executive Other than for Good Reason.    In the event that, prior to the Expiration Date, Executive terminates his employment other than for Good Reason,
(i) Executive shall be entitled to his Accrued Obligations and the Company shall have no further obligation to Executive and (ii) Executive shall immediately resign as a Director. 

 

	 	6.7	Expiration of the Term. 

  

	 	6.7.1	Upon the Expiration Date, the Executive shall retire and his employment with the Company shall cease. Executive shall be entitled to (i) his Accrued Obligations and any Prior Bonus and (ii) the payments and
benefits provided for under Sections 6.4.1 (if not previously paid) and 6.4.2 above, and the Company shall have no further obligation to Executive. The payments and benefits provided under clause (ii) of this Section 6.7 shall be subject
to Executive entering into a complete release of all claims in the form then applicable under the Company’s Executive Severance Plan (or any successor to such plan). All amounts payable under this Section 6.7 shall be in lieu of and not in
addition to any amount that otherwise might be payable under the Company’s Executive Severance Plan (or successor to such plan) upon such a termination. 

  

	 	6.7.2	In the event Executive’s employment continues past 2015 and into 2016, the Company and Executive shall discuss whether additional incentive compensation opportunities are appropriate. 

 

	7.	Confidential Information. 

  

	 	7.1	 During the period of Executive’s employment and at all times thereafter, Executive shall protect and not disclose Proprietary Information, except
as may be required to discharge his duties hereunder or if Executive is required by law, regulation, or court order to disclose any Proprietary Information. “Proprietary Information” is all information, whether or not reduced to writing
(or in a form from which information can be obtained, translated, or derived into reasonably 

  
 6 

	 	
usable form) or maintained in the mind or memory of Executive and whether compiled or created by the Company, any of its subsidiaries or any affiliates of the Company or its subsidiaries
(collectively, the “Company Group”), which derives independent economic value from not being readily known to or ascertainable by proper means by others who can obtain economic value from the disclosure or use of such information, of a
proprietary, private, secret or confidential (including, without exception, inventions, products, processes, methods, techniques, formulas, compositions, compounds, projects, developments, sales strategies, plans, research data, clinical data,
financial data, personnel data, computer programs, customer and supplier lists, trademarks, service marks, copyrights (whether registered or unregistered), artwork, and contacts at or knowledge of customers or prospective customers) nature
concerning the Company Group’s business, business relationships or financial affairs; provided however, that Proprietary Information shall not include any information that (i) has become generally available to the public other than as a
result of a disclosure by Executive, or (ii) was available or became known to Executive prior to the disclosure of such information on a non-confidential basis without breach of any duty of confidentiality from any party to the Company and
Executive. 

  

	 	7.2	Executive further agrees that his obligation not to disclose or to use information and materials of the types, and his obligation to return materials and tangible property, set forth in this Section 7 also extends
to such types of information, materials and tangible property of customers of the Company Group, consultants for the Company, suppliers to the Company, or other third parties who may have disclosed or entrusted the same to the Company or to
Executive. 

  

	 	7.3	Executive’s obligations under this Section 7 are in addition to, and not in limitation of, all other obligations of confidentiality under the Company’s policies, general legal or equitable principles or
statutes. 

  

	8.	Statements to Third Parties. 

  

	 	8.1	During the period of Executive’s employment and at all times thereafter, other than in connection with the performance of his duties hereunder, Executive shall not, directly or indirectly, make or cause to be made
any statements, including but not limited to, comments in books or printed media, to any third parties criticizing or disparaging the Company Group or commenting on the character or business reputation of the Company Group and resulting in a
material adverse impact upon the Company. Without the prior written consent of the Board, unless otherwise required by law, Executive shall not (i) publicly comment in a manner materially adverse to the Company Group concerning the status,
plans or prospects of the business of the Company Group or (ii) publicly comment in a manner materially adverse to the Company Group concerning the status, plans or prospects of any existing, threatened or potential claims or litigation
involving the Company Group; provided, nothing herein shall preclude honest and good faith reporting by Executive to appropriate Company or legal enforcement authorities. 

  
 7 

	 	8.2	During the period of Executive’s employment and at all times thereafter, other than in connection with the performance of the duties of Company senior executives (other than Executive), the Company shall use its
best efforts to cause the senior executives of the Company (other than Executive) to not, directly or indirectly, make or cause to be made any statements, including but not limited to, comments in books or printed media, to any third parties
criticizing or disparaging Executive or commenting on the character or business reputation of Executive, and resulting in a material adverse impact upon Executive. Nothing herein shall preclude honest and good faith reporting by the Company or its
senior executives (other than Executive) to appropriate legal enforcement authorities. 

  

	9.	Non-Competition.    For a period commencing on the Effective Date and continuing for twenty-four (24) months following Executive’s termination of employment for any reason
(the “Restricted Period”), Executive covenants and agrees that Executive shall not, directly or indirectly, engage in any activities on behalf of or have an interest in any Competitor of the Company Group, whether as an owner, investor,
executive, manager, employee, independent consultant, contractor, advisor, or otherwise, other than ownership of less than one percent (1%) of any class of stock in a publicly traded corporation. A “Competitor” is any entity doing
business directly or indirectly (as an owner, investor, provider of capital or otherwise) in the United States including any territory of the United States (the “Territory”) for whom no less than 5% of such entity’s gross annual
revenues for the preceding year are attributable to products or services that are the same or similar to the products or services that are being provided by any member of the Company Group at the time of Executive’s termination or that were
provided by a member of the Company Group during the two-year period prior to Executive’s termination of employment; provided, however, that any separate subsidiary or distinct division of a Competitor which contributed less than 5% of such
entity’s gross annual revenues for the preceding year shall also be a Competitor if Executive provides services or advise to it. Executive acknowledges and agrees that due to the continually evolving nature of the Company Group’s industry,
the scope of its business or the identities of Competitors may change over time. Executive further acknowledges and agrees that the Company Group markets its products and services on a nationwide basis, encompassing the Territory and that the
restrictions imposed by this covenant, including the geographic scope, are reasonably necessary to protect the Company Group’s legitimate interests. 

  

	10.	Non-Solicitation.    Executive hereby covenants and agrees that he shall not during the Restricted Period, directly or indirectly, individually or on behalf of any other person or
entity: 

  

	 	10.1	Hire or employ or assist in hiring or employing any person who was at any time during the last 6 months of Executive’s employment an employee, representative or agent of any member of the Company Group or solicit,
aid, induce or attempt to solicit, aid, induce or persuade, directly or indirectly, any person who is an employee, representative, or agent of any member of the Company Group to leave his or her employment with any member of the Company Group to
accept employment with any other person or entity provided, however, the foregoing shall not prohibit advertisements for employment placed in newspapers or other media of general circulation to the general public; or 

  
 8 

	 	10.2	Solicit any customer of the Company Group, or any person or entity whose business the Company Group had solicited during the 180-day period prior to termination of Executive’s employment for purposes of business
which is competitive to the Company Group within the Territory. 

  

	11.	Developments.    Executive acknowledges and agrees that he shall make full and prompt disclosure to the Company of all inventions, improvements, discoveries, methods, developments,
software, mask works, and works of authorship, whether patentable or copyrightable or not, (i) which relate to the Company’s business and have heretofore been created, made, conceived or reduced to practice by Executive or under his
direction or jointly with others, and not assigned to prior employers, or (ii) which have utility in or relate to the Company’s business and are created, made, conceived or reduced to practice by Executive or under his direction or jointly
with others during his employment with the Company, whether or not during normal working hours or on the premises of the Company (all of the foregoing of which are collectively referred to in this Agreement as “Developments”). Executive
further agrees to enter into the Company’s standard form of invention and disclosure agreement that is required of all new employees. Executive further agrees to cooperate fully with the Company, both during and his employment with the Company,
with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and other countries) relating to Developments. Executive shall not be required to incur or pay any
costs or expenses in connection with the rendering of such cooperation. 

  

	12.	Remedies.    Executive and the Company agree that the covenants contained in Sections 7, 8, 9, 10 and 11 (the “Covenants”) are reasonable under the circumstances, and further
agree that if in the opinion of any court of competent jurisdiction any such Covenant is not reasonable in any respect, such court shall have the right, power and authority to sever or modify any provision or provisions of such Covenants as to the
court will appear not reasonable and to enforce the remainder of the covenants as so amended. Executive acknowledges and agrees that the remedy at law available to the Company for breach of any of Executive’s obligations under the Covenants
would be inadequate and that damages flowing from such a breach may not readily be susceptible to being measured in monetary terms. Accordingly, Executive acknowledges, consents and agrees that, in addition to any other rights or remedies that the
Company may have at law, in equity or under this Agreement, upon adequate proof of Executive’s violation of any Covenant, the Company shall be entitled to immediate injunctive relief and may obtain a temporary order restraining any threatened
or further breach, without the necessity of proof of actual damage or of posting any bond. 

  

	13.	Indemnification; Insurance.    The Company’s standard form of director and officer indemnification agreement, as previously entered into by Executive and the Company, shall remain
in effect as of and following the Effective Date. In addition, the Executive shall be covered, both during and up to 24 months after the Expiration Date, by director and officer liability insurance to the maximum extent that such insurance covers
any officer or director, or former officer or director, as applicable, of the Company. 

  
 9 

	14.	Representation; Legal Restrictions.    Executive represents and warrants to the Company that Executive is not a party to any contract, agreement or understanding, written or oral,
including, without limitation, any agreement containing any non-competition, non-solicitation, confidentiality or other restrictions on your activities, which could prevent Executive from entering into this Agreement or performing all of
Executive’s duties and obligations hereunder, other than as has been disclosed by Executive. 

  

	15.	Withholding.    The Company may withhold from any and all amounts payable under this Agreement such federal, state and local taxes as may be required to be withheld pursuant to any
applicable law or regulation. 

  

	16.	Notice.    For the purposes of this Agreement, notices, demands and all other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly
given when delivered or (unless otherwise specified) mailed by registered mail, return receipt requested, postage prepaid, addressed as set forth above, or to such other address as any party may have furnished to the other in writing in accordance
herewith, except that notices of change of address shall be effective only upon receipt. 

  

	17.	Miscellaneous. 

  

	 	17.1	The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Delaware. 

 

	 	17.2	Sections 6, 7, 8, 9, 10, 11, 12, 13, 15, 16 and such provisions of Section 17 as are relevant of this Agreement shall remain in full force and effect and shall survive the termination of Executive’s employment
and the expiration or other termination of this Agreement. 

  

	 	17.3	Any dispute, controversy or question arising under, out of, or relating to this Agreement (or the breach thereof), or, Executive’s employment with the Company or termination thereof, other than those disputes
relating to Executive’s alleged violations of Sections 7, 8.1, 9, 10 and 11, or the Company’s alleged violation of Section 8.2, of this Agreement shall be referred for binding arbitration in Toledo, Ohio. Such arbitration shall be
conducted in accordance with the National Rules for Resolution of Commercial Disputes of the American Arbitration Association (“Rules”). The parties shall select a neutral arbitrator and this shall be the sole means for resolving such
dispute; provided, if the parties are unable to agree to an arbitrator, an arbitrator will be selected in accordance with the Rules. The Company shall pay the costs of the arbitration. If the Executive prevails on at least one material issue in any
proceeding before such an arbitrator, the Company shall reimburse the Executive for the reasonable legal fees and expenses incurred by the Executive in such arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court
having jurisdiction thereof. This Section 17.3 shall not apply to any action by the Company to enforce Sections 7, 8.1, 9, 10 or 11, or by Executive to enforce Section 8.2, of this Agreement and shall not in any way restrict the
Company’s remedies under Section 12 of this Agreement. 

  
 10 

	 	17.4	It is the intent of the parties that this Agreement be administered so as to comply with Section 409A of the Internal Revenue Code of 1986 (“Section 409A”) and all applicable regulations. The parties
intend that any payment due hereunder shall be delayed or adjusted as deemed reasonably necessary to avoid the imposition of Section 409A penalties upon Executive. Without limiting the generality of the foregoing and any provision in this
Agreement to the contrary notwithstanding, if any portion of the payments or benefits to be received by Executive under this Agreement would be considered deferred compensation under Section 409A, then the following provisions shall apply to
the relevant portion: 

  

	 	17.4.1	For purposes of this Agreement, no payment that would otherwise be made and no benefit that would otherwise be provided upon a termination of employment shall be made or provided unless and until such termination of
employment is also a “separation from service” (as determined in accordance with Section 409A); 

  

	 	17.4.2	If Executive is a “specified employee” (within the meaning of Section 409A and determined pursuant to procedures adopted by the Company) at the time of a separation from service, each portion of such
payments and benefits that would otherwise be payable pursuant to this Agreement upon a separation from service during the six (6) month period immediately following the separation from service shall instead be paid or made available on the
earlier of (i) the first business day of the seventh month following the date Executive incurs a separation from service, and (ii) Executive’s death (the applicable date, the “Permissible Payment Date”); 

 

	 	17.4.3	With respect to any amount of expenses eligible for reimbursement under this Agreement, such expenses shall be reimbursed by the Company within 60 calendar days (or, if applicable, on the Permissible Payment Date)
following the date on which the Company receives the applicable invoice from Executive but in no event later than December 31 of the year following the year in which Executive incurs the related expense; 

 

	 	17.4.4	Payments delayed under this Section 17.4 as a result of the application of Section 409A shall not accrue interest. In no event shall the reimbursements or in-kind benefits to be provided by the Company in one
taxable year affect the amount of reimbursements or in-kind benefits to be provided in any other taxable year, nor shall Executive’s right to reimbursement or in-kind benefits be subject to liquidation or exchange for another benefit; and

  

	 	17.4.5	Each payment under this Agreement shall be considered a “separate payment.” 

  

	 	17.4.6	 If Executive’s termination of employment occurs on or after November 1st of a calendar
year, any payment that otherwise would have been paid to Executive between Executive’s date of termination and the end of the 

  
 11 

	 	
calendar year (and which are contingent upon Executive entering into a complete release of all claims), will be paid to Executive as soon as practicable in the following calendar year and on or
before the 90th day following the Executive’s date of termination. 

  

	 	17.5	The Executive shall not be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement, and such amounts shall
not be reduced whether or not the Executive obtains other employment. 

  

	 	17.6	The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.

  

	 	17.7	Any waiver, alteration, amendment or modification of any of the terms of this Agreement shall be valid only if made in writing and signed by each of the parties hereto; provided, however, that any such waiver,
alteration, amendment or modification is consented to on the Company’s behalf by the Board or a Committee or member thereof as may be duly authorized by the Board. No waiver by either of the parties hereto of their rights hereunder shall be
deemed to constitute a waiver with respect to any subsequent occurrences or transactions hereunder unless such waiver specifically states that it is to be construed as a continuing waiver. 

 

	 	17.8	This Agreement, and Executive’s rights and obligations hereunder, may not be assigned or delegated by him. The Company may assign its rights, and delegate its obligations, hereunder to any subsidiary or affiliate
of the Company, or any successor to the Company, specifically including the Covenants. The rights and obligations of the Company under this Agreement shall inure to the benefit of and be binding upon its respective successors and assigns. The rights
and obligations of Executive under this Agreement shall inure to the benefit of and be binding upon his heirs and legatees. 

  

	 	17.9	This Agreement constitutes the entire understanding and agreement of the parties hereto regarding the employment of Executive. This Agreement supersedes (i) the Executive Employment Agreement dated April 18,
2011 by and between the Company and Executive, which is hereby terminated, and (ii) all prior negotiations, discussions, correspondence, communications, understandings and agreements between the parties relating to the subject matter of this
Agreement. 

  

	 	17.10	The headings of the sections and subsections of this Agreement are inserted for convenience only and shall not be deemed to constitute a part thereof, affect the meaning or interpretation of this Agreement or of any
term or provision hereof. Words of one gender shall be interpreted to mean words of another gender when necessary to construe this Agreement, and in like manner words in singular may be interpreted to be in the plural, and vice versa. Use of the
word “or” shall mean “either or both” and use of the word “including” shall be “without limitation.” 

  
 12 

	 	17.11	This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. The execution of this Agreement may be
by actual or facsimile signature. 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the date first above
written. 
  

									
	Dana Holding Corporation	 		 	
					
	By:	 	 /s/ J. C Muscari
	 		 		 	 /s/ Roger Wood

	Name:	 	Joseph C. Muscari	 		 		 	Roger Wood
	Title:	 	Chairman	 		 		 	

  
 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]